Biotech News

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Corcept (CORT)Corcept2026-09-18 12:00 ESTCommercial

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Sep. 18, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

Related news

CORTCorcept2026-06-17 20:28 EST

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-05-27 12:00 EST

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

NBIXNeurocrine Biosciences2026-05-18 12:46 EST

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

NBIXNeurocrine Biosciences2026-07-23 20:05 EST

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

CRNXCrinetics Pharmaceuticals2026-06-02 20:05 EST

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

CRNXCrinetics Pharmaceuticals2026-03-26 20:05 EST

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

AMPHAmphastar Pharmaceuticals, Inc.2020-10-06 10:00 EST

Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection

View all latest news

Corcept

Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...

Recent company news

CORTCorcept2026-11-03 21:05 EST

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-10-27 20:05 EST

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORTCorcept2026-10-26 12:00 EST

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

CORTCorcept2026-10-20 20:00 EST

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

CORTCorcept2026-09-23 12:00 EST

Corcept Announces Planned Leadership Transition

Stock data

Close: 71.63 USD
Market cap: 7.64B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States